Trustcore Financial Services LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 120 shares of the life sciences company’s stock, valued at approximately $44,000.
Several other large investors have also recently made changes to their positions in the company. Strategy Asset Managers LLC purchased a new stake in Illumina in the 1st quarter valued at approximately $26,000. Financial Advocates Investment Management lifted its stake in Illumina by 1,430.0% in the 4th quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock valued at $28,000 after buying an additional 572 shares in the last quarter. C J Advisory Inc purchased a new stake in Illumina in the 1st quarter valued at approximately $29,000. Valeo Financial Advisors LLC lifted its stake in Illumina by 130.0% in the 1st quarter. Valeo Financial Advisors LLC now owns 115 shares of the life sciences company’s stock valued at $36,000 after buying an additional 65 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. purchased a new stake in Illumina in the 1st quarter valued at approximately $37,000. 90.75% of the stock is currently owned by institutional investors and hedge funds.
ILMN traded down $1.99 during trading on Wednesday, hitting $289.95. The company’s stock had a trading volume of 281,303 shares, compared to its average volume of 1,804,498. The business has a 50 day simple moving average of $331.46. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.10 and a current ratio of 6.79. The stock has a market cap of $42.40 billion, a PE ratio of 50.69, a PEG ratio of 2.77 and a beta of 1.10. Illumina, Inc. has a twelve month low of $268.62 and a twelve month high of $380.76.
A number of equities research analysts recently issued reports on ILMN shares. Deutsche Bank reduced their target price on Illumina from $290.00 to $280.00 and set a “hold” rating on the stock in a research note on Friday, July 12th. Credit Suisse Group reaffirmed a “buy” rating and issued a $340.00 target price on shares of Illumina in a research note on Wednesday, July 31st. ValuEngine lowered Illumina from a “buy” rating to a “hold” rating in a research note on Friday, July 19th. Wolfe Research started coverage on Illumina in a research note on Thursday, May 30th. They issued an “outperform” rating on the stock. Finally, Canaccord Genuity lowered Illumina from a “buy” rating to a “hold” rating and reduced their target price for the company from $330.00 to $300.00 in a research note on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $330.92.
In other Illumina news, SVP Omead Ostadan sold 1,260 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $315.32, for a total value of $397,303.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Francis A. Desouza sold 3,000 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $301.25, for a total value of $903,750.00. Following the completion of the transaction, the chief executive officer now owns 64,200 shares of the company’s stock, valued at $19,340,250. The disclosure for this sale can be found here. Insiders sold a total of 60,991 shares of company stock valued at $19,789,080 over the last quarter. 0.38% of the stock is currently owned by insiders.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: What are popular green investing opportunities?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.